Calculate the relative frequency of an event for
a changing number of trials.
Not exact matches
These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount
of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability
of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction
of generic versions
of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect
of lowering prices or reducing the
number of insured patients; the possibility
of unfavorable results from clinical
trials involving investigational compounds; Gilead's ability to initiate clinical
trials in its currently anticipated timeframes; the levels
of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits
of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages
of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development
of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to
changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate
of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).
«We have analysed all the data and feedback and reviewed a
number of incidents including the George Smith one and we have made a few
changes,» said Kemp, speaking at Twickenham on the eve
of the new Premiership season where the
trial will continue.
Hearing those complaints, Gov. Andrew Cuomo proposed
changes in his budget plan but they were rejected, having drawn criticism from a
number of disparate but politically potent groups including unions,
trial lawyers and the state medical society.
«The STAMPEDE
trial is
changing the face
of prostate cancer because the flexibility
of the
trial design means that we can investigate a
number of different treatment options rapidly and in parallel, enabling scientists to get results much more quickly than they usually would.
«Previous studies suggest that reducing heart fat is feasible through weight loss or weight management, but these studies only looked at small
numbers of people and there have been no clinical
trials linking cardiovascular outcomes with heart fat
changes due to weight management interventions.
In an editorial accompanying the published article in Circulation, experts from the Technische Universität and the Munich Heart Alliance, Gjin Ndrepepa and Adnan Kastrati, affirmed that, if confirmed by a subsequent analysis
of large
numbers of patients, the results
of METOCARD - CNIC
trial are likely to lead to a
change in clinical practice: «In this regard, a pharmaco - protective strategy able to reduce infarct size by 20 percent when used in conjunction with primary PCI nurtures great hope in clinical benefit.»
If you don't have the time to invest in the career, the game does offer faster races like quick race or time
trials, including
changing the
number of laps.
In addition to the Infinite Pack
trial, update 2.0 brings with it a
number of user experience
changes to make Ghost Recon Phantoms more accessible than ever.
There are a
number of factors that can
change the duration
of the
trial as well, so the timeline provided can never be assured with certainty.
[The researchers] estimate that for New York City, their algorithm's advice could cut crime by defendants awaiting
trial by as much as 25 percent without
changing the
numbers of people waiting in jail.
«The downward shift in the
number of jury
trials in recent years is forcing
changes in how litigation is practiced, and redefining skill - sets
of the current generation
of young lawyers, in ways that eventually will reshape the legal system.
It is not coincidence that a centuries - long history
of dispute resolution through
trial changed so rapidly once women entered the legal profession in significant
numbers.
Few, if any, law school classes allude to the realities
of well - documented and hardly «new»
changes in legal practice including: the «vanishing»
trial, clients who no longer want to buy into the paternalism
of the I'll - take - care -
of - it - for - you model, or the extraordinarily large
number of self - represented litigants who can not afford full representation.
In my humble opinion, that's got to
change if the appeals courts want the bar and the public, as well as the parties before it, to be guided by their opinions and to act on them in a manner (i.e., settling cases for reasonable amounts) that will reduce the
number of lawsuits brought to
trial and appealed.»
He drove a
number of change initiatives, such as Justice on Target (that reduced, for the first time in 18 years, the time to
trial and the
number of court appearances per criminal case), a health and safety initiative that reduced workplace injuries by 20 % in 3 years, the 4 Pillars
of Family Reform, Civil Justice Reform, the largest funding increase in Legal Aid's history, and was part
of a new approach to indigenous relations recognized by the United Nations.
It may be that the
trial was underpowered to pick up the level
of changes that could represent a valuable
change at the population level where smaller differences have great impact because
of the
numbers involved.